Michael J. Dowling is president and chief executive officer of Northwell Health, which delivers world-class clinical care throughout the New York metropolitan area, pioneering research at the Feinstein Institute for Medical Research and a visionary approach to medical education highlighted by the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the School of Graduate Nursing and Physician Assistant Studies.
Northwell Health is the largest integrated health care system in New York State with a total workforce of more than 66,000 employees — the state’s largest private employer. With 23 hospitals, 6,675 hospital and long-term care beds, more than 665 outpatient physician practices and a full complement of long-term care services, Northwell is one of the nation’s largest health systems, with $11 billion in annual revenue.
Prior to becoming president and CEO in 2002, Mr. Dowling was the health system’s executive vice president and chief operating officer. Before joining Northwell Health in 1995, he was a senior vice president at Empire Blue Cross/Blue Shield. Mr. Dowling served in New York State government for 12 years, including seven years as state director of Health, Education and Human Services and deputy secretary to the governor. He was also commissioner of the New York State Department of Social Services.
Before his public service career, Mr. Dowling was a professor of social policy and assistant dean at the Fordham University Graduate School of Social Services, and director of the Fordham campus in Westchester County.
Mr. Dowling has been honored with many awards over the years. They include: his selection as the Grand Marshal of the 2017 St. Patrick’s Day Parade in New York City; induction into the Irish America Hall of Fame; the 2012 B’nai B’rith National Healthcare Award, the Ellis Island Medal of Honor, the 2011 Gail L. Warden Leadership Excellence Award from the National Center for Healthcare Leadership, the 2011 CEO Information Technology Award from Modern Healthcare magazine and the Healthcare Information and Management Systems Society, the National Human Relations Award from the American Jewish Committee, the Distinguished Public Service Award from the State University of New York’s Nelson A. Rockefeller College of Public Affairs and Policy, an Outstanding Public Service Award from the Mental Health Association of New York State, an Outstanding Public Service Award from the Mental Health Association of Nassau County, the Alfred E. Smith Award from the American Society for Public Administration, and the Gold Medal from the American Irish Historical Society. For 11 consecutive years, Modern Healthcare has ranked Mr. Dowling on its annual list of the “100 Most Powerful People in Healthcare.” In March 2016, Mr. Dowling was also listed No. 1 on Long Island Press’ 2015 “Power List” recognizing the 50 most-influential Long Islanders.
Mr. Dowling is chair of the Healthcare Institute and the Institute for Healthcare Improvement (IHI). He is a member of the Institute of Medicine of the National Academies of Sciences and the North American Board of the Smurfit School of Business at University College, Dublin, Ireland. He also serves as a board member of the Long Island Association. He is past chair and a current board member of the National Center for Healthcare Leadership (NCHL), the Greater New York Hospital Association (GNYHA), the Healthcare Association of New York State (HANYS) and the League of Voluntary Hospitals of New York. Mr. Dowling was an instructor at the Center for Continuing Professional Education at the Harvard School of Public Health.
Mr. Dowling grew up in Limerick, Ireland. He earned his undergraduate degree from University College Cork (UCC), Ireland, and his master’s degree from Fordham University. He also has honorary doctorates from Queen’s University Belfast, University College Dublin, Hofstra University, Dowling College and Fordham University
Sue Siegel is GE’s Chief Innovation Officer and CEO of Business Innovations, as of October 2017. In this role, she is responsible for leading the development and acceleration of innovation across the company. An innovator at heart, she is a seasoned executive focused on uncovering new and unconventional paths to growth. She has 30+ years of corporate, entrepreneurial and venture capital experience all geared at one thing: turning untapped potential into real value.
Sue joined GE in 2012 as CEO of healthymagination. Sue helped launch GE Ventures, an innovation engine focused on accelerating promising start-ups, creating new business models, developing new markets, and nurturing ideas into scalable initiatives both inside and outside of GE. In this role, Sue and her team led the creation and launch of seven new companies including Avitas Systems, Vineti and Evidation Health, funded and accelerated growth for 100+ companies and led the creation of a novel licensing model for GE’s library of patents – connecting technology and ideas to create new avenues to growth.
Prior to joining GE, Sue worked for a Silicon Valley-based venture capitalist at MDV, Sue led investments and served as Board member for companies in personalized medicine, digital health, and life sciences. Prior to that, Sue served as President and Board Member of Affymetrix (NASDAQ: AFFX), where she led the company’s transformation from a pre-revenue startup to a global, multi-billion dollar market cap genomics leader. She also led strategy, technology development, licensing, manufacturing, and new market creation and development at leading organizations including Bio-Rad, DuPont and Amersham.
Sue holds an M.S. from Boston University School of Medicine and a B.S. from the University of Puerto Rico. She has been recognized in Fortune as one of “34 Leaders Who Are Changing Health Care” and as one of “The 100 Most Influential Women in Silicon Valley” by Silicon Valley Business Journal. She is an Aspen Institute Crown Fellow and was featured as a “Multiplier” in the bestselling book: “Multipliers: How the Best Leaders Make Everyone Smarter.” She lives in Silicon Valley with her husband and has two sons. She is an avid hiker and loves to spend time on the scenic trails of Northern California.
Current board positions and memberships:
Align Technology (NASDAQ: ALGN), MIT The Engine, Harvard Partners’ Healthcare Innovation Advisory Board, Scientific Advisory Board, Brigham and Women’s Hospital, Stanford Medicine Board of Fellows, University of California’s Innovation Council, USC’s Schaeffer Center for Health Policy and Marshall School of Business Board of Leaders, Women Corporate Directors, and Member of YPO Gold.
Paul Black serves as Allscripts Chief Executive Officer. Paul was appointed CEO in December 2012 after having served on Allscripts Board of Directors for eight months. As Chief Executive Officer, Paul leads the direction of the company and its global commitment to delivering an Open, Connected Community of HealthTM.
Prior to joining Allscripts, Paul spent more than 13 years with Cerner Corporation in various executive positions, retiring as Cerner’s Chief Operating Officer in 2007. During his tenure with Cerner, he helped build the company into a market leader in healthcare information technology with more than $1.5 billion in annual revenue. Prior to Cerner, Paul spent 12 years with IBM Corporation in a variety of leadership positions in sales, product marketing and professional services.
Paul has held positions on multiple private company and non-profit boards of directors. The businesses ranged from healthcare information technology and healthcare services to software and SaaS-based consumer Internet marketing. Paul’s leadership experience on those boards includes serving as director, chairman and executive Chairman. Paul has also provided investment advice to several private equity firms on both coasts.
He is currently Immediate Past Chairman of Truman Medical Centers, as well as an Officer of the Corporation. Truman Medical Centers is a 400-bed safety net academic hospital in Kansas City. Paul earned a Bachelor of Science degree from Iowa State University and a Master of Business Administration from the University of Iowa. He is married with two children and enjoys running, travel and coaching youth sports.
Kevin J. Tracey, is President and CEO of The Feinstein Institute for Medical Research; Professor of Neurosurgery and Molecular Medicine at the Zucker School of Medicine at Hofstra-Northwell; and Executive Vice President, Research, at Northwell Health, in New York. A leader in the fields of inflammation research and bioelectronic medicine, his contributions to science include discovery and molecular mapping of neural circuits that control immune responses; identifying HMGB1, an abundant component in cell nuclei, as a therapeutic target at the intersection of sterile and infective inflammation; and identifying the therapeutic anti-inflammatory activity of monoclonal anti-TNF antibodies. Professor Tracey received his B.S. (Chemistry, summa cum laude, Phi Beta Kappa) from Boston College in 1979, and his M.D. from Boston University in 1983. He trained in neurosurgery from 1983 to 1992 at the New York Hospital-Cornell University Medical, Center, and was a guest investigator at the Rockefeller University, before moving in 1992 to The Feinstein Institute in New York. An inventor with more than 60 United States patents, and author of more than 360 scientific publications, he is also cofounder of the Global Sepsis Alliance, a non-profit organization supporting the efforts of >1 million caregivers in more than 70 countries. His honors and awards include a Doctorate honoris causa from the Karolinska Institute, Stockholm, Sweden and lectureships from Harvard, Yale, Rockefeller University, the NIH, and elsewhere. He has been elected or inducted into the American Society of Clinical Investigation (2001), the American Association of Physicians (2009), the Long Island Technology Hall of Fame (2012), Alpha Omega Alpha (2014), and is a Fellow in the American Association for the Advancement of Science. Professor Tracey is also the author of “Fatal Sequence.”
Stephanie Cuskley is the Chief Executive Officer of the Helmsley Charitable Trust which aspires to improve lives by supporting exceptional nonprofits and other mission-aligned organizations in the U.S. and around the world in health, place-based initiatives, and education and human services. Appointed in late 2015, she brings to her role more than 30 years of diverse management and leadership experience from both the corporate and nonprofit sectors.
Stephanie began her career as an investment banker, most recently with JPMorgan Chase, where she spent many years in leveraged finance. In 2001, shortly after the merger of JPMorgan and Chase, Stephanie led the firm’s new leadership and culture program, initially focused on the firm’s top 200 executives and subsequently expanded to all employees. More recently, from 2009 to 2015, Stephanie was CEO of NPower, a nonprofit focused on mobilizing the technology community and providing individuals, nonprofits, and schools opportunities to build tech skills and achieve their potential.
Today, Stephanie serves on the board of Aegion, Inc. She earned her B.A. from the University of Toronto and holds an MBA from Cornell University.
Josh has worked with NEA since 1995 and recently became a General Partner on their healthcare team leading the medtech/healthtech practice. Josh is the Founder & Executive Chairman of ExploraMed, a medical device incubator creating 8 companies. Transactions from the ExploraMed portfolio include NeoTractm acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, Nuelle and Willow. Josh serves on the faculty of the Stanford University Medical School as a Adjunct Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program. Josh serves on the board of Setpoint Medical, DOTS Devices, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT.
Dr. Patrick Carroll is the Chief Medical Officer for Walgreen’s Healthcare Clinics. In this role, Dr. Carroll oversees all matters pertaining to provision of care, clinical outcomes, patient safety, healthcare information systems and strategic initiatives and programs that will enhance the care model. In addition, Dr. Carroll is instrumental in implementing care management programs, managing relationships with health systems and collaborating with the Clinical Office in the development of enterprise clinical programs.
Prior to joining Walgreen’s in May 2015, Dr. Carroll served as the Chief Medical Officer of Integrated Care Partners, Hartford HealthCare’s clinical integration organization. He was also the Medical Director for Hartford HealthCare’s Medicare Shared Savings Program which currently has over 20,000 patients in a Medicare/CMS shared-risk pilot program. He played a key role in leading the Hartford HealthCare’s efforts in the transition to value-based care in a time of a rapidly changing healthcare landscape.
From 2010–2012, Dr. Carroll served as the Chief Medical Officer for the Granite Medical Group in Quincy, Massachusetts. Granite Medical Group is a 40-provider Multispecialty/Primary Care Group which is part of Atrius Health, a 1000 Medical Provider Group.
Dr. Carroll received his bachelor’s degree from the College of the Holy Cross and his medical degree from Dartmouth Medical School. He completed his residency training at Middlesex Hospital in family practice, where he served as Chief Resident.
Dr. Carroll is Board Certified in Family Practice and in Adolescent Medicine.
Aletha Maybank, MD, MPH currently serves as a Deputy Commissioner in the New York City Department of Health and is the Founding Director of the Center for Health Equity. The Center’s mission is to bring an explicit focus to health equity in all of the Department’s work by tackling structural barriers, such as racism, ensuring meaningful community engagement, and fostering interagency coordination in neighborhoods with the highest disease burden.
Prior to this role, she was an Assistant Commissioner in the NYC Health Department and served as the Director of the Brooklyn Office, a place-based approach. Dr. Maybank also successfully launched the Office of Minority Health as its Founding Director in the Suffolk County Department of Health Services in NY from 2006-2009.
Dr. Maybank serves as Vice President of the Empire State Medical Association, the NYS affiliate of the National Medical Association. In the media and on the lecture circuit, she has appeared or been profiled on Disney Jr.’s highly successful Doc McStuffins Animated Series, ESSENCE Facebook live and their Festival’s Empowerment Stage, MSNBC’s Melissa Harris-Perry show, and various other outlets. She has also advised on the award-winning documentary Soul Food Junkies by Byron Hurt and Black Women in Medicine by Crystal Emery. For her accomplishments, she has won numerous awards.
Dr. Maybank holds a BA from Johns Hopkins University, a MD from Temple University School of Medicine, and a MPH from Columbia University Mailman School of Public Health. A pediatrician board certified in Preventive Medicine/Public Health, she completed her preventive medicine residency at the SUNY Stony Brook University School of Medicine and her pediatrics residency at the Albert Einstein School of Medicine’s Schneider Children’s Hospital.
Troyen A. Brennan, M.D., M.P.H., is Executive Vice President and Chief Medical Officer of CVS Health. Prior to joining CVS Health, Dr. Brennan was Chief Medical Officer of Aetna Inc. In a previous academic career, he was Professor of Medicine at Harvard Medical School, and Professor of Law and Public Health at Harvard School of Public Health.
Patrick Lincoln, Ph.D., is director of the Computer Science Laboratory at SRI International. He is also the executive director of SRI’s program for the Department of Homeland Security’s Cyber Security Research and Development Center and director of the SRI Center for Computational Biology. Lincoln leads research in the fields of formal methods, computer security and privacy, computational biology, scalable distributed systems, and nanoelectronics.
He has led multidisciplinary groups conducting high-impact research projects in symbolic systems biology, scalable anomaly detection, exquisitely sensitive biosensor systems, strategic reasoning and game theory, and privacy-preserving data sharing. He has published dozens of influential papers, holds several patents, has served on scientific advisory boards for private and publicly held companies, nonprofits, and government agencies and departments.
Lincoln holds a Ph.D. in computer science from Stanford University and a B.Sc. in computer science from MIT. He has previously held positions at MCC, Los Alamos National Laboratory, and ETA Systems.
Lincoln was named an SRI Fellow in 2005.
Ritesh is Chief Digital Officer for Ogilvy in the Health & Wellness practice.
He is responsible for providing digital vision, leadership and guidance for our Health & Wellness customers globally.
He joins Ogilvy after 4 years as the Chief Digital officer at Ogilvy CommonHealth, the specialist healthcare agency within WPP where, working with the creative and planning groups, Ritesh and his team provided digital strategy, technology development and innovation services, via the Ogilvy Digital Health Lab, to bring client campaigns to life for the digital world.
During his tenure, Ritesh and his team have created many new innovations for clients, from EHR Strategy, to the use of A/R, V/R Chat Bots and voice activated systems for marketers.
Prior to joining Ogilvy CommonHealth, Ritesh spent 5 years as the Global Head of Digital & Innovation at inVentiv Health where he worked on a number of projects on the clinical side of the business as well as the commercial side. In clinical, Ritesh worked to digitize the CRO and create digital patient recruiting solutions. In the commercial group, Ritesh worked on many the highly successful campaigns, including work for Allergan for Botox,, Latisse and Lapband, as well as Drive4copd to raise awareness of COPD. He and his team also pioneered the use of Social Media in Pharma marketing for clients in 2011, winning a Clio award for a campaign for Cystic Fibrosis using Facebook and Twitter.
He joined InVentiv after a stint as the SVP and Managing Director of HealthEd Digital—the digital arm of the HealthEd Group, a patient education agency based in Clark, New Jersey. There he worked on a number of digital projects, including branded and unbranded patient education sites.
Ritesh joined HealthEd after working at Cushman & Wakefield, a global real estate services company, where he was responsible for rolling out a global CRM solution for the company.
Ritesh has also been involved in several startups in his career. Most recently, he was the cofounder of Avivocom. As the CTO, Ritesh created a technology that uses a combination of video, VoIP and text chat to allow clients to converse with online prospects through banner ads. It is now widely used by IBM, Verizon, Intel, Adobe and other large corporations.
Ritesh co-founded Avivocom after working at Euro RSCG, where he was the Global CIO. He was responsible for Information Technology Strategy and Operations for the fifth-largest advertising and media company in the world. Ritesh joined Euro RSCG after four and a half years as the Vice President of Technology for Agency.com in New York, where he managed a global team of professionals creating the technical infrastructures for web-based applications.
Lori Melichar, a labor economist, is a director at the Foundation where she focuses on discovering, exploring and learning from cutting edge ideas with the potential to help create a Culture of Health. She is also the host of the Foundation’s Pioneering Ideas podcast.
Previously at the Foundation, Melichar managed several programs to focus a broad research community on studies to improve health and health care policy and practice, and was a key driver of efforts to advance the science of quality improvement (QI) research and evaluation.
Prior to joining the Foundation in 2002, she served with the National Institutes of Child Health and Development and the Demography of Inequality initiative at the University of Maryland Center on Population, Gender and Inequality. Melichar also worked at Pfizer Pharmaceuticals as a consultant and economic policy analyst and at the Project Hope Center for Health Affairs.
She holds a PhD and MA in economics from the University of Maryland at College Park and a BA in economics from Swarthmore College in Pennsylvania.
An Oklahoma native, Melichar resides in New York City with her husband and three children.
Dr. Paul Rothman is the Dean of the Medical Faculty for the Johns Hopkins University School of Medicine and Chief Executive Officer of Johns Hopkins Medicine, a $8 billion academic medical enterprise and a health system with a global reach. As Dean/CEO, Dr. Rothman oversees both the Johns Hopkins Health System and the School of Medicine. A rheumatologist and molecular immunologist, he came to Hopkins in July 2012 after having served as Dean of the Carver College of Medicine at the University of Iowa and leader of its clinical practice plan since 2008. Previously, he served as Head of Internal Medicine at the University of Iowa, beginning in 2004, and prior to that as Vice Chairman for Research and Founding Director of the Division of Pulmonary, Allergy and Critical Care Medicine at Columbia University College of Physicians and Surgeons, where he joined the faculty in 1990.
A 1980 Phi Beta Kappa graduate of the Massachusetts Institute of Technology, Rothman received his Medical degree from Yale University in 1984, earning a place in the Alpha Omega Alpha Honor Medical Society. He then trained at Columbia-Presbyterian Medical Center in internal medicine and rheumatology and accepted a postdoctoral fellowship at Columbia University prior to joining its medical school faculty.
Rothman’s research focused on immune system molecules known as cytokines. Specifically, he investigated the role these molecules play in the normal development of blood cells, as well as the abnormal development of these blood cell that leads to leukemia. He also studied the role of cytokines in immune system responses to asthma and allergies. His work was consistently funded by the National Institutes of Health.
His honors include a James S. McDonnell Foundation Career Development Award, a Pfizer Scholars Award, a Pew Scholar Award, a Leukemia Society of America Scholar Award and the Pharmacia Allergy Research Foundation International Award in 1997. Dr. Rothman is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Clinical Investigation. He served as President of the Association of American Physicians and was elected as a Fellow of the American Association for the Advancement of Sciences. Dr. Rothman serves on the Board of Merck and Co.
Vivek Ramaswamy is founder and Chief Executive Officer of Roivant Sciences. The Roivant family of companies includes multiple wholly-owned or majority-owned biopharmaceutical subsidiaries, each focused on a different disease area. With its affiliates, Roivant has raised over $2.8 billion in capital to date to fund clinical programs and pursue adjacent business opportunities in healthcare.
Prior to founding Roivant, Mr. Ramaswamy was an investor in the biotechnology sector. He currently serves as a member of the board of directors of Roivant Sciences and as chairman of the boards of directors of Axovant Sciences, Myovant Sciences, and Arbutus Biopharma Corporation. He received an A.B. summa cum laude in biology from Harvard College and a J.D. from Yale Law School.
Kenneth Stein, MD, FACC, FHRS, is currently Senior Vice President and Chief Medical Officer for Rhythm Management and Global Health Policy at Boston Scientific. Ken is a Phi Beta Kappa graduate of Harvard College (in Economics), and earned his MD from New York University School of Medicine. He completed his medical internship and residency at The New York-Presbyterian Hospital/Weill Cornell Medical Center, where he also completed his cardiology and cardiac electrophysiology training.
Prior to joining Boston Scientific in 2009, Dr. Stein held the position of Associate Director of Clinical Cardiac Electrophysiology at Weill Cornell Medical Center and Associate Professor of Medicine at Cornell University where he was widely published, authoring over 125 peer-reviewed scientific publications in the areas of cardiac electrophysiology with special interest in cardiac resynchronization therapy and risk stratification for sudden cardiac arrest. Dr. Stein currently oversees the clinical trials, medical safety, and medical education and clinical communications for Boston Scientific’s Cardiac Rhythm Management, Electrophysiology and Watchman Left Atrial Appendage Closure businesses as well as leading the corporate Global Health Policy team tasked with shaping the company’s policies with respect to global health care delivery and reimbursement.
Dr. Stein serves on the board of the Boston Scientific Political Action Committee and on the Scientific Advisory Board of Optum Labs. Since 2013, he has also served on the board of Childrens HeartLink, a registered 501c(3) nonprofit organization that trains and mentors medical teams in underserved parts of the world to diagnose and treat children with heart disease. Founded in 1969, Children’s HeartLink currently supports partner hospitals in Brazil, China, India, Malaysia, Ukraine and Vietnam.
Ramon Soto is Senior Vice President, Chief Marketing and Communications Officer, for Northwell Health, where he is responsible for the development and execution of Northwell’s brand strategy and all aspects of marketing and communications, including public relations, digital engagement, strategic and clinical marketing, internal communications and customer acquisition. Northwell Health is New York’s largest healthcare provider with 4 million patient visits per year in a network of 23 hospitals and 650 community, research and clinical facilities.
Ramon is the former chief marketing officer for Magellan Health, a healthcare services company, and previously was a senior vice president at Aetna, managing the global marketing function for Aetna’s commercial business.
Ramon received his B.A. from the State University of New York at Binghamton and his MBA from the Yale School of Management with a concentration in Healthcare. He serves on the Yale School of Management Alumni Board of Directors.
Imran is the founding partner at Action Potential Venture Capital, GSK’s corporate venture capital fund focused on investing in companies that pioneer bioelectronic medicines and their enabling technologies. Imran represents Action Potential as a board member in NeuSpera Medical, SetPoint Medical, Presidio Medical and Qionics. Prior to his role at Action Potential, Imran headed up GSK’s Investment Management group and was responsible for accessing technology and innovation external to GSK by making and managing investments in life science venture capital funds as limited partners and direct investments in biotechs. Imran has been with GSK for over 12 years, primarily in various business development functions leading and participating in in-licenses, out-licenses, research collaborations, co-development and co-promotion arrangements, equity investments, and M&A deals. Imran has trained as a Canadian Chartered Accountant and is based in Boston, MA.
Kelly graduated from Centenary College of New Jersey in 2012 earning her degree in English Literature and Secondary Education. While she is no longer in the classroom, she continues to be an advocate for educational equity for underprivileged students and believes that teachers should be at the center of education policy.
As a person that has battled Crohn’s disease for 16 years, she ended up in Amsterdam in 2017 to get a revolutionary new device called a Vagus Nerve Stimulator that put her into remission for the first time since diagnosis. Nowadays, she spends her days managing a shop in Montclair, NJ, freelance writing, designing curriculum, and advocating for the bioelectronic medicine that has saved her life.
As a previous luxury Hotel Executive, Mr. Gierlinger brings a unique perspective to the patient experience dialogue. However, it was his personal patient experience spending three months in hospitals that motivates him to challenge the status quo in healthcare. Now as Chief Experience Officer for Northwell Health, one of the largest Integrated Delivery Networks in the country, Mr. Gierlinger is driving culture transformation grounded in patient centeredness and empathy.
Mr. Gierlinger came to Northwell Health from the Henry Ford Health System in Detroit where he served as Vice President, Hospitality and Service Culture, responsible for creating a superior and consistent service experience for patients, visitors and employees. Mr. Gierlinger worked closely with leadership to drive culture change around improving the customer experience in every encounter across the system. Prior to that, he was an Administrator, Hospitality Services, for Henry Ford West Bloomfield Hospital, responsible for all aspects of non-clinical operations, the Wellness & Integrative Health Center, retail shops and café, and the customer experience. Additionally, he was an integral part of the team, leading the efforts to achieve the acclaimed Malcom Baldridge National Quality Award.
Mr. Gierlinger began his career in the luxury hotel business, holding a series of leadership positions with the Ritz-Carlton Hotel Company. He played a key role in the openings of several Ritz-Carlton hotels in Germany, Japan, Indonesia and the U.S., responsible for executing and implementing Ritz-Carlton service standards, training staff, and leading teams of trainers.
Mr. Gierlinger is an Executive Board member at The Beryl Institute and the Founding Council member of the Institute of Innovation.
He received a bachelor’s degree in hospitality business administration from the Bavaria Hotel Management Academy, Altoetting, Germany.
Elaine Brennan is one of the leaders of True North, a Northwell Health entity established to develop and invest in innovative products, technologies and services that will generate revenue to support the health system’s mission of delivering quality care, innovative research and education.
Ms. Brennan joined Northwell to create Pharma Ventures, a group tasked with establishing an innovative approach to managing and developing more collaborative and strategic relationships with the pharmaceutical industry.
Previously, Ms. Brennan was the CEO of Socrates, a health care information technology company, where she led the development and launch of its electronic health records system in the US. She also worked with Enterprise Ireland, managing the Irish life sciences companies entering the US market and founded also founded Gastroenterology Ireland, which combined a cluster of companies, research and development, and Irish opinion leaders in Ireland and the US.
Her pharmaceutical career at Roche, Bristol Myers Squibb and AbbVie included marketing/sales and clinical roles launching blockbuster products in the virology sector.
Ms. Brennan has published scientific articles on genetic engineering and biodegradable polymers applications, and patented many products in the same area. She earned her science degree in the United Kingdom and her early education in County Galway and Belgium.
Prof. Chad Bouton is the VP of Advanced Engineering and the Director of the Center for Bioelectronic Medicine at The Feinstein Institute for Medical Research, the research arm of the Northwell Health System in New York. Professor Bouton formerly served as research leader at Battelle Memorial Institute—the world’s largest independent research and development organization—where he spent 18 years researching and developing biomedical technology. At the Feinstein Institute, he is performing groundbreaking research in neurotechnology to treat paralysis and is developing new technologies to accelerate the field of bioelectronic medicine. Professor Bouton’s pioneering work, allowing a paralyzed person for the first time to regain movement using a brain implant, has been featured on 60 Minutes, CBS, and presented at TEDx. He holds over 70 patents worldwide and his technologies have been awarded three R&D 100 Awards and he was recognized by the US Congress for his work in the medical device field. He has been named Inventor of the Year and Distinguished Inventor by Battelle, and was selected by the National Academy of Engineering in 2011 to attend the Frontiers in Engineering Symposium.
Tyler Mathisen co-anchors CNBC’s “Power Lunch” (M-F, 1PM-3PM ET), one of the network’s longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network’s events team to grow the rapidly expanding business.
Previously, Mathisen was co-anchor of “Nightly Business Report,” an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network’s daily content and coverage. He was also co-anchor of CNBC’s “Closing Bell.”
Mathisen has reported one-hour documentaries for the network including “Best Buy: The Big Box Fights Back,” “Supermarkets Inc: Inside a $500 Billion Money Machine” and “Death: It’s a Living.” Mathisen was also host of the CNBC series “How I Made My Millions.”
Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine’s mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.
In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on “Caring for Aging Parents,” which aired on ABC’s “Good Morning America.” Mathisen served as money editor of “GMA” from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York’s WCBS-TV.
A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.
Dr. Tara Narula is a board certified cardiologist and is an Assistant Professor of Cardiovascular Medicine at the Zucker School of Medicine, Associate Director of the Cardiac Care Unit at Lenox Hill Hospital in Manhattan and a CBS News Medical Contributor. She contributes to various CBS News broadcasts and platforms including “CBS this Morning”, “CBS Evening News”, “CBSN” and “CBS Sunday Morning”. She is also a frequent contributor to O, Oprah Magazine. She joined Lenox Hill Heart & Vascular Institute of New York in 2010 and provides outpatient consultative care as well as inpatient cardiac critical care. She is additionally board certified in Nuclear Cardiology, Echocardiography and Internal Medicine. After graduating from Stanford University with degrees in Economics and Biology, she was founder and CEO of her own small business, Sun Juice Inc. Subsequently she obtained her medical degree at USC Keck School of Medicine where she graduated with Alpha Omega Alpha Society Honors. Dr. Narula completed her residency in internal medicine at Harvard University/Brigham and Women’s Hospital and her fellowship training in cardiology at New York Presbyterian-Weill Cornell Medical Center. Dr. Narula is currently a fellow of the American College of Cardiology (FACC). She serves as a member for both the NYC Go Red for Women Committee and is a national spokesperson for the AHA. She is a recipient of the Super Doctors Rising Star Award for NYC 2014 through 2018. Her interests include preventive cardiology, women’s health and the management of coronary artery disease.
Uwe Schoenbeck leads Pfizer’s External Science & Innovation (ES&I) team, which is responsible for enhancing Pfizer’s Worldwide R&D pre-clinical and clinical pipeline by introducing novel targets, prosecuting externally sourced cutting edge science through partnership with academia, and harnessing innovative assets and breakthrough technologies through partnerships with Biotech and Pharma.
ES&I is composed of three key pillars: a global External Search & Evaluation and Venture Investment team working across Pfizer’s therapeutic priority areas and sourcing transformative assets and technologies via scouting, seed funding, and NewCo formation; a team focused on novel target and biology discovery research to help drive rejuvenation of the pipeline and enhance Confidence in Rational in our programs; and the Centers for Therapeutic Innovation (CTI), a global externally-networked academic partnership for drug co-development. This end-to-end innovation capability aims to strengthen Pfizer’s research engine and be a key driver of a pipeline of truly differentiated first-in-class pipeline assets as well as breakthrough technologies by effectively combining external innovation with Pfizer’s internal drug development capabilities.
Dr. Schoenbeck brings fifteen years of pharmaceutical drug development experience to Pfizer’s R&D executive leadership team and Senior Leadership Committee. Prior to joining the company, he served as Vice President, Cardiovascular Research for Boehringer Ingelheim. Before joining industry, he held an Assistant Professor of Medicine position with Brigham & Women’s Hospital, Harvard Medical School. Uwe has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, review articles/book chapters and abstracts with particular contributions in molecular & cell biology, cardiovascular research, immunology, and metabolism.
Thomas is the head of health care investing at Qualcomm Ventures where he focuses on digital health care companies. Thomas is also a General Partner at dRx Capital, which is a joint venture investment company launched by Novartis and Qualcomm with a capital commitment up to $100M. As part of these roles, Thomas strives to catalyze the success of digital medicine products, services and business models by investing in high-growth, technology companies.
Prior to Qualcomm Ventures, Thomas was an investment professional at Providence Ventures, the venture capital arm at one of the nation’s leading healthcare delivery networks, Providence St. Joseph Health. Prior to Providence Ventures, Thomas was part of the strategic finance / strategic investing team at Cambia Health Solutions, the private equity sponsor for Regence Blue Cross Blue Shield, a nationally recognized health insurer committed to transforming healthcare. As part of his role at Cambia, Thomas had an observer seat on the Fund Management Team (FMT), the formal governing body established by the company to approve all VC, PE and M&A deals. Thomas was also a direct investment professional at Adams Street Partners where he supported the partnership on venture capital and growth equity opportunities.
Thomas holds his Master of Science in Medical Informatics and a Bachelor of Science in Biomedical Engineering from Northwestern University where he is a published author in the Journal of Surgical Oncology.
Chef Bruno Tison is the VP of Food Services and Corporate Chef within the Office of Patient & Customer Experience. Committed to delivering a world-class food experience for our patients, and building a healthy workplace for employees, Chef Tison is responsible for promoting consistency and elevating the quality of food and beverage throughout the organization.
As a 30+ year hospitality industry veteran that includes Executive Chef of the legendary Plaza Hotel in New York City, Chef Tison’s nouvelle cuisine has earned extensive critical acclaim. Tison comes to Northwell from the Fairmont Sonoma Mission Inn and Spa in California – a Condé Nast “Top Ten” rated Spa & Resort. There he successfully led the team in receiving the celebrated Michelin Star recognition for three consecutive years.
Prior to joining the Plaza Hotel, Chef Tison trained with several of France’s legendary master chefs. Under their tutelage, Tison developed and refined his own unique style. He also worked in some of America’s most prestigious kitchens such as Beau Geste, in New York City, Ernie’s Restaurant and Pierre at Le Meridien, in San Francisco.
A native of northern France, Chef Tison began his culinary education at Belgium’s prestigious Institut Technique Des Metiers De L’Alimentation, where he graduated with highest honors and was awarded first prize for excellence in culinary achievement. Chef Tison is also a member of the Société Culinaire Philantropique in New York City.
His immense passion for healthy foods along with an extensive breadth of experience drives Chef Tison to make an impactful difference within the healthcare environment.
Dr. Chernoff is a molecular diagnostics and biopharmaceutical industry veteran who has played pivotal roles in moving early stage R&D programs successfully through clinical development and product commercialization and evaluating a broad range of in-licensing opportunities. He oversees all clinical development activities for SetPoint as the company continues to advance its bioelectronic medicine platform, reporting to Anthony Arnold, Chief Executive Officer of SetPoint Medical.
Prior to joining SetPoint, Dr. Chernoff has served as a translational medicine consultant to more than 40 biotechnology, pharmaceutical and medical device companies and has held chief medical officer posts with a number of companies, including Crescendo Bioscience, Adamas Pharma, XDX, CardioDX, Tethys Biosciences and Aquinox Pharma. Dr. Chernoff was Vice President of Corporate Technology at Elan Pharmaceuticals and Medical Director at Chiron Diagnostics, where he played a pivotal role in the development of viral load assays for HIV, HCV, HBV and CMV. He was a principal with life sciences management consulting firm Keelin Reeds Ventures and entrepreneur in residence and operating partner at TPG Biotech VC Fund. He received a Bachelor of Science degree in molecular biology from Yale University and an MD from New York University and completed his medical training and research in internal medicine, rheumatology and infectious disease at the University of California San Francisco Medical Center. He also served as Chief Resident in Internal Medicine at San Francisco General Hospital and Assistant Chief of Medicine at UCSF Medical Center.
Mike leads business development and partnerships for Google Brain. His charter includes working with large healthcare systems to move research ideas into translational research/products and partnerships. During his tenure at Google he has also led business development at Google [X]/Google Life Sciences, was part of the early founding group to create Google Capital – Google’s private equity investment vehicle, led the creation of the Google Play Store for Android products, and led acquisitions and investments within the Corporate Development Group. Prior to working at Google, Mike held positions at McCown DeLeeuw and Goldman Sachs. Mike received his MBA from Harvard Business School and a Bachelors at Emory University in Economics & Italian studies.
Shyam focuses on corporate strategy development at Avanos, a Medical Devices company. Shyam has responsibility for technology M&A and strategic alliances. Shyam joined the corporate development team at Kimberly-Clark Corp., where led various New Business Development initiatives before transitioning into Avanos as part of the spin-off of the Kimberly-Clark healthcare. Prior to joining Kimberly-Clark, Shyam was a group leader within the pharmaceutical R&D group at Abbott Labs, now AbbVie. At Abbott, Shyam led various API development projects. Shyam received his Ph.D. in chemistry from the University of Toledo and an MBA from the University of Chicago.
At GlaxoSmithKline Ian currently focuses on the execution of corporate and business development projects in the Pharmaceutical, Vaccines, and Consumer Healthcare businesses. Ian has worked on early stage research collaborations, clinical stage development assets, and commercial collaborations of marketed products. Ian started his career with Merck as a biochemist in Oncology drug discovery focused on a program in the signal transduction pathway that resulted in a clinical stage asset. After working as a sales representative for Eli Lilly, Ian took on marketing and finance roles that supported strategy planning and business development at Bristol-Myers Squibb before transitioning into business development. Ian gained experience in business development at Bristol-Myers Squibb as a director on both the transactions team and the search and evaluation team focusing on innovative R&D discovery projects and clinical stage assets.
Jennifer Gregoire is social impact executive specializing in global health, marketing & communications, international development and philanthropy.
Known as an expert in building and scaling mission driven initiatives, Jennifer brings more than 20 years of global leadership experience in both corporate and non-profit settings. She also brings deep expertise in strategic planning, operations, program development, strategic partnerships, advocacy and new business development. And, with extensive work experience in Africa, Asia and Latin America, Jennifer is highly experienced in working on the ground in emerging markets.
Jennifer has held leadership roles with with Medtronic; Orbis; Starwood Hotels & Resorts; the Clinton Health Access Initiative (CHAI); Lindblad Expeditions & National Geographic; and the International Peace Institute at the United Nations.
Jennifer holds a B.S. from Cornell University and a M.S. from Florida State University.
Sree Sreenivasan is a leading social and digital media consultant and trainer, working with nonprofits, startups, companies and executives around the world. He has served as Chief Digital Officer of New York City, the Metropolitan Museum of Art and Columbia University (where he was a full-time professor of journalism for 20+ years). He is in the midst of a 25-city, 10-country workshop tour. In 2015, he was named to Fast Company’s list of Most Creative People in Business.
As Senior Vice President of Northwell Ventures, Tom Thornton is responsible for identifying and fostering innovative ideas that enhance the growth of the health system’s clinical and nonclinical enterprises.
In this role, he works with senior leadership to develop and advance clinical and nonclinical ideas, bringing them into practice and the market and building strategic partnerships and relationships within the broader regional ecosystem. Mr. Thornton manages all the Northwell innovation programs, including technology commercialization, enterprise growth and investment management.
Prior to Northwell, Mr. Thornton led the Healthcare Innovation Alliance at Cleveland Clinic Innovations, a program aimed at forming multi-institutional collaborations to foster and accelerate the commercialization of medical innovations.